Insulet (PODD) reported $488.5 million in revenue for the quarter ended June 2024, representing a year-overyear increase of 23.2%. EPS of $0.55 for the same period compares to $0.38 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $463.13 million, representing a surprise of +5.48%. The company delivered an EPS surprise of -3.51%, with the consensus EPS estimate being $0.57. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Insulet (PODD) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -3.51%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $0.39 per share when it actually produced earnings of $0.73, delivering a surprise of 87.18%. Over the last four qua ...

Table of Contents _____________________________________________________ ________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q _____________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE ...

Exhibit 99.1 Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue, Gross Margin and Operating Margin Guidance ACTON, Mass. - August 8, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended June 30, 2024. ® Second Quarter Financial Highlights: 1 • Second quarter 2024 revenue of $488.5 million, up 23 ...

Insulet (PODD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Therefore, the Zacks rating upgrade for Insulet basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Fundamentally speaking, rising earnings estimates and the consequent rating upgrade f ...

Timothy Scannell, former President and Chief Operating Officer of Stryker Located in Massachusetts' healthcare hub, CereVasc, Inc., is a clinical stage, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, encompasses first-ever, groundbreaking percutaneous transvenous-transdural access to the central nervous system intended to allow the first minimally invasive treatment for communicating h ...

Company Developments - Insulet Corp. announced the availability of its Omnipod 5 Automated Insulin Delivery system in France, integrated with Dexcom's G6 sensor, and launched the system with G7 compatibility in the United States [1][5] - The Omnipod 5 App for iPhone has been released in a limited market, making Insulet the first company to offer a tubeless AID system fully controllable from a smartphone [3][9] - The Omnipod 5 system is now available for individuals aged two years and above with Type 1 diabetes, and it has received reimbursement status from the French National Authority for Health [8] Market Insights - The global insulin delivery devices market was valued at $12.5 billion in 2021 and is projected to grow at a CAGR of 7.4% by 2030 [4][10] - The increasing prevalence of diabetes due to aging, obesity, and unhealthy lifestyles is driving demand for advanced insulin delivery devices [10] Competitive Landscape - Insulet's Omnipod 5 system is compatible with both Dexcom G6 and Abbott's FreeStyle Libre 2 Plus CGM sensors, expanding its market reach in Europe [5][8] - Insulet's stock has seen a decline of 31.1% over the past year, contrasting with the industry's decline of 1.7% [12] Recent Clinical Results - Positive results from a randomized controlled trial (OP5-003) demonstrated improved glycemic and patient-reported outcomes in Type 1 diabetes patients using Omnipod 5, showing its superiority over standard pump therapy [20]

Insulet Corporation (PODD) is primed for growth in the coming quarters as its revolutionary Omnipod 5 offering continues to successfully drive market growth. The company is making remarkable progress in terms of its key strategic imperatives to help patients in their diabetes management. Sound financial stability further instills optimism. The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $13.46 billion. Insulet projects a long-term estimated earnings gro ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style ...

Insulet Corporation (PODD) reported GAAP earnings per share (EPS) of 73 cents for first-quarter 2024, which significantly improved from the year-ago period's EPS of 34 cents. The figure also exceeded the Zacks Consensus Estimate by 87.2%. First-quarter 2023 adjusted earnings per share were 23 cents. Revenues Revenues in the first quarter totaled $441.7 million, beating the Zacks Consensus Estimate by 4.3%. The top line jumped 23.3% year over year (up 22.8% at the constant exchange rate or CER). CER growth e ...